Formoterol/budesonide pressurized metered-dose inhaler: A guide to its use in chronic obstructive pulmonary disease

被引：0

作者：

Lyseng-Williamson K.A. ^{[1
]}

机构：

[1] Springer, North Shore, 0754 Auckland, Mairangi Bay

来源：

Drugs & Therapy Perspectives | 2014年 / 30卷 / 8期

关键词：

Chronic Obstructive Pulmonary Disease; Budesonide; Formoterol; Severe Chronic Obstructive Pulmonary Disease; Indacaterol;

D O I：

10.1007/s40267-014-0142-4

中图分类号：

学科分类号：

摘要：

The use of a single pressurized metered-dose inhaler (pMDI) containing both formoterol (a long-acting β2-selective adrenoreceptor agonist) and budesonide (an inhaled corticosteroid) is an effective, convenient and well- tolerated option for the treatment of adults with symptoms of moderate to severe chronic obstructive pulmonary disease (COPD) and a history of recurrent COPD exacerbations. Two inhalations of formoterol/budesonide pMDI 6/200 μg twice daily provided rapid and durable improvements in lung function, as well as improvements in COPD control, COPD symptoms and health status outcomes, in clinical trials in patients with moderate to very severe COPD. © 2014 Springer International Publishing.

引用

页码：269 / 275

页数：6

共 21 条

[1]

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated 2014

[2]

Kew K.M., Dias S., Cates C.J., Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: A network meta-analysis, Cochrane Database Syst Rev, 3, (2014)

[3]

Ehrick J.D., Wylie J., Goodey A.P., Et al., Orally inhaled fixed-dose combination products for the treatment of asthma and chronic obstructive pulmonary disease: Not simple math, Ther Deliv, 5, 3, pp. 297-317, (2014)

[4]

Nannini L.J., Poole P., Milan S.J., Et al., Combined corticosteroid and long-acting beta2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease, Cochrane Database Syst Rev, 8, (2013)

[5]

Eklund A., Tronde A., Johannes-Hellberg I., Et al., Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: Four open-label, randomized, crossover studies in healthy adults, Biopharm Drug Dispos, 29, 7, pp. 382-395, (2008)

[6]

Vannair® 6/100 Mcg/inhalation and Vannair® 6/200 Mcg/inhalation (Formoterol Fumarate Dihydrate/budenoside): Brazilian Prescribing Information (In Portuguese), (2014)

[7]

Vannair® 100/6 and Vannair® 200/6 Metered Dose Inhaler: New Zealand Data Sheet, (2013)

[8]

Symbicort® 80/4.5 and 160/4.5 Inhalation Aerosol: US Prescribing Information, (2012)

[9]

Tronde A., Gillen M., Borgstrom L., Et al., Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD, J Clin Pharmacol, 48, 11, pp. 1300-1308, (2008)

[10]

Tashkin D.P., Et al., Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: Results of a 6-month randomized clinical trial, Drugs, 68, 14, pp. 1975-2000, (2008)

← 1 2 3 →